Sun, Jan 25, 2015, 5:09 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • jiarealty jiarealty Feb 14, 2013 12:49 PM Flag

    The IMGN fix is in....

    Analysts, paid bashers, and shorts will try to convince you that IMGN is not worth #$%$ prior to Feb 26th T-DM1 decision date. You get discouraged, panic, and sell. Bashers tells you somehow, the current price already figures in T-DM1 approval....If you think about so???? How to they know how much revenue T-DM1 can bring in, how do they know the impact a vaildated TAP technology has on the rest of IMGN pipeline, how do they know what potential partnerships or acquisition possibilites is coming down ? The answer is ...THEY DON''T. Since the Oppenheimer analysts downgraded IMGN to $14, IMGN have already lost 8% of its value. I just cannot see how IMGN will stay flat when T-DM1, a potential billion dollar blockbuster will get approved and an army of Genentech reps will be promoting this billion dollar drug. The reality is also that many physicians will be using T-DM1 as a first line agent well before completion of Marianne trial because T-DM1 saves lives. I don't know about you, but a cancer patient may not want to wait for failure before reaching for T-DM1. Potentially, T-DM1 sales can far exceed analyst's expecatations....Oh...wait...current price also does not reflect European approval...... IMGN long and strong...don't let shorts and bashers frazzle your nerves.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
6.33+0.2600(+4.28%)Jan 23 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.